chufangao/CTO huggingface dataset:
Clinical trial NCT02959554: Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
Official title: A Randomized Phase II Study With NIVOlumab or Continuation of Therapy as an Early SWITCH Approach in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) and Disease Control After 3 Months of Treatment With a Tyrosine Kinase Inhibitor
Acronym: NIVOSWITCH
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-31
Primary completion date: 2020-08-31
Completion date: 2021-01-31
Plan to share individual participant data: NO
Clinical trial NCT04541186: Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
Sponsor: 89bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 86.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-09-01
Primary completion date: 2022-05-19
Completion date: 2022-05-31
Baseline population: Safety Analysis Set: All participants who received at least 1 dose of study drug. Participants are summarized by treatment received.~As per SAP, since a low number of participants enrolled in the fibrate cohort, participants randomized to pegozafermin 27 mg QW fibrate cohort were combined with the pegozafermin 27 mg QW main cohort, forming a pooled pegozafermin 27 mg QW group for analyses. Similarly, the placebo participants in the fibrate cohort were combined with the main placebo group.
Limitations and caveats: The study did not separately evaluate the response to pegozafermin in participants who were on and who were not on concurrent fibrate therapy due to small sample size in the Fibrate Expansion cohort.
Plan to share individual participant data: NO
Clinical trial NCT02368886: Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Official title: Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 123.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-03-27
Primary completion date: 2017-09-01
Completion date: 2023-03-02
Baseline population: The data for the pre-emptive and reactive treatment with clobatasol were pooled for the comparison of the two dosing strategies (regorafenib dose escalation group (Arms A1 + A2) versus regorafenib standard dose group (Arms B1 + B2)).
Clinical trial NCT05144217: Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
Official title: Impact of Different Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo in a Prospective Controlled Dose Finding Phase IIb Trial
Acronym: SILVER
Sponsor: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: recruitment period has been reached its end
Enrollment: 156.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2021-06-23
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02600429: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
Official title: Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1
Sponsor: ReGenTree, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-17
Primary completion date: 2019-11-20
Completion date: 2020-03-09
Baseline population: \[Not Specified\]
Plan to share individual participant data: NO
Clinical trial NCT05420961: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
Official title: A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 717.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-07-12
Primary completion date: 2023-05-16
Completion date: 2023-05-16
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04818320: Favipiravir in High-risk COVID-19 Patients
Official title: Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial
Sponsor: Penang Hospital, Malaysia (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 500.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-16
Primary completion date: 2021-07-01
Completion date: 2021-07-13
Plan to share individual participant data: NO
Clinical trial NCT05081388: COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Official title: A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 25.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-11-08
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Limitations and caveats: Due to the reduced activity of REGN14256+Imdevimab against the emerging Omicron variant and not due to any safety concerns, study enrollment was paused and later terminated in the phase 1 portion of the study. Phase 2 and phase 3 portions of the study were never opened. As a result, and due to small sample size, not all of the original objectives and endpoints were analyzed as planned
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Clinical trial NCT02570347: Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
Official title: Routine vs. Clinically-Directed Antibiotic Treatment in Snake Bite With Local Envenomation: a Randomised Controlled Trial
Acronym: RADIANS
Sponsor: Jawaharlal Institute of Postgraduate Medical Education & Research (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slower than anticipated recruitment and emergent COVID-19 situation
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-03
Primary completion date: 2019-10-24
Completion date: 2020-03-31
Clinical trial NCT01817426: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission
Official title: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study
Acronym: STOP IT
Sponsor: Copenhagen University Hospital at Herlev (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-31
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Clinical trial NCT03177187: Combination Study of AZD5069 and Enzalutamide.
Official title: ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination with Enzalutamide, in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Acronym: ACE
Sponsor: Institute of Cancer Research, United Kingdom (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Discontinuation of production of IMP
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-13
Primary completion date: 2022-09-15
Completion date: 2022-11-16
Plan to share individual participant data: NO
Clinical trial NCT03021317: Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses
Official title: Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses
Acronym: ACTHAR
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Terminated early due to lack of resources.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-20
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Baseline population: No participants started the trial and received the intervention.
Plan to share individual participant data: NO
Clinical trial NCT04254679: Pilot Trial: Postoperative Opioid-free Analgesia
Official title: Opioid-free Analgesia After Outpatient General Surgery: A Pilot Randomized Controlled Trial
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-29
Primary completion date: 2020-09-20
Completion date: 2020-12-03
Clinical trial NCT04865419: Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Official title: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Trial terminated based on benefit-risk profile assessment
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-11
Primary completion date: 2023-08-08
Completion date: 2023-08-08
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at:~https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:~https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
Clinical trial NCT03881111: First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Withdrawn due to protocol amendment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-21
Primary completion date: 2021-05-11
Completion date: 2022-05-11
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03324243: A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Official title: A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Sponsor: Arog Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn: Study halted prior to enrollment of first participant
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03850444: Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
Official title: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 262.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-01
Primary completion date: 2018-09-04
Completion date: 2022-09-08
Baseline population: All randomized participants
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04106700: Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Official title: Venous Thromboembolism Prophylaxis With Apixaban in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma Receiving Induction Therapy With an Immunomodulatory-based Regimen
Sponsor: Instituto de Investigacion Sanitaria La Fe (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 60.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-12
Primary completion date: 2020-08-26
Completion date: 2020-10-05
Plan to share individual participant data: NO
Clinical trial NCT04252430: RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
Official title: Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function
Sponsor: MedDay Pharmaceuticals SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to other phase 3 trial failure to meet primary endpoint
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-09
Primary completion date: 2020-03-17
Completion date: 2020-03-17
Clinical trial NCT05355805: Hidradenitis Suppurativa Phase 2b Study of Izokibep
Official title: A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Sponsor: ACELYRIN Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 205.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-05-05
Primary completion date: 2023-08-02
Completion date: 2024-02-21
Baseline population: Full analysis set
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04993443: First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
Official title: A Single and Multiple-dose Escalation First-in-Human Study Evaluating the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Administered Via Inhalation and IV Infusion in Healthy Subjects and Patients With Mild Asthma.
Sponsor: Syneos Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Copmeletion of Part A SAD cohorts, sponsor cancelled Part B-D cohorts
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-06
Primary completion date: 2023-03-02
Completion date: 2023-03-09
Plan to share individual participant data: NO
Clinical trial NCT02942758: Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
Official title: Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy
Acronym: AML-ViVA
Sponsor: University Hospital Regensburg (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to financial reasons.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-10
Primary completion date: 2020-03-25
Completion date: 2020-03-25
Plan to share individual participant data: NO
Clinical trial NCT03339921: Botulinum for Chronic Exertional Compartment Syndrome
Official title: Comparison of Botulinum Toxin to Fasciotomy in Treatment of Chronic Exertional Compartment Syndrome
Acronym: Botox
Sponsor: 375th Medical Group, Scott Air Force Base (FED)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: This study is being closed because it is unworkable.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-07
Primary completion date: 2020-05-01
Completion date: 2020-05-01
Baseline population: This study was terminated because it is unworkable.
Limitations and caveats: This study was terminated because it is unworkable.
Plan to share individual participant data: NO
Clinical trial NCT04128696: Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Official title: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Acronym: INDUCE-3
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The trial was stopped by the sponsor based on assessment of the clinical data
Enrollment: 315.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-21
Primary completion date: 2021-04-27
Completion date: 2023-06-20
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a data sharing agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT02272699: Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Official title: Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma
Sponsor: Peking University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under re-design.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-11-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04476043: To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 209.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-08-25
Primary completion date: 2021-12-15
Completion date: 2023-08-16
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT05232227: Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Official title: Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Trial terminated by funder
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-20
Primary completion date: 2023-06-05
Completion date: 2023-10-30
Plan to share individual participant data: NO
Clinical trial NCT03781960: Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Official title: Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Safety letter from sponsor
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-31
Primary completion date: 2022-04-29
Completion date: 2022-04-29
Limitations and caveats: Early termination leading to small numbers of subjects analyzed
Plan to share individual participant data: NO